RECRUITINGOBSERVATIONAL

DSLT for Reducing Medication in Glaucoma

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma

About This Trial

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult patients scheduled to undergo DSLT treatment in one or both eyes. - Diagnosis of ocular hypertension or primary open angle glaucoma (POAG). - Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg. Who Should NOT Join This Trial: - Previous glaucoma surgeries/interventions: - Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt). - Patients who have undergone cataract surgery within the prior 2 years. - Secondary glaucoma: - Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases. - Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Adult patients scheduled to undergo DSLT treatment in one or both eyes. * Diagnosis of ocular hypertension or primary open angle glaucoma (POAG). * Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg. Exclusion Criteria: * Previous glaucoma surgeries/interventions: * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt). * Patients who have undergone cataract surgery within the prior 2 years. * Secondary glaucoma: * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases. * Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.

Treatments Being Tested

DEVICE

Voyager DSLT

Locations (1)

The Eye Institute of West Florida

Largo, Florida, United States